Medicines List

Description

Ranitidine is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Ranitidine is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives.

Indications

Short-term treatment of acute duodenal ulcer

Ranitidine – Tchaikapharma is efficient in short-term treatment of duodenal ulcer. Most patients are cured in four weeks.

Maintenance therapy of duodenal ulcer

The percentage of recurrence of duodenal ulcer in patients on maintenance therapy after healing of duodenal ulcer is lower than in subjects not given the maintenance dose of the medicinal product.

Short-term treatment of acute benign gastric ulcer

Most patients are cured in six weeks.

Maintenance therapy after remission of gastric ulcer

In patients with cured gastric ulcer, maintenance therapy is recommended with reduced Ranitidine – Tchaikapharma doses for prevention of ulcer recurrence.

Reflux esophagitis

Ranitidine – Tchaikapharma is used for treatment of reflux esophagitis, when standard therapy has produced no effect.

Treatment of pathologic conditions, running with the hiperacides.

Subject to medical prescription

Pharmaceutical form: 150 mg x 20 film-coated tablets

NHIF code: AF152          ICD: K20; K25.7; K26.7

Description

Atenolol is a selective β1 receptor antagonist, a drug belonging to the group of beta blockers, a class of drugs used primarily in cardiovascular diseases.

Indications

• Hypertension.
• Chronic stable angina pectoris.
• Secondary prevention following an acute myocardial infarction
• Supraventricular arrhythmias:

– supportive therapy in sinus tachycardia caused by thyrotoxicosis;

– paroxysmal supraventricular tachycardia (therapeutically or prophylactically);

– atrial fibrillation and atrial flutter; in cases of insufficient response to maximum dosages of cardiac glycosides; as supportive therapy in thyrotoxicosis; if cardiac glycosides are contraindicated or if there is an unfavourable risk/benefit ratio.

• Ventricular arrhythmias:

– ventricular extra systoles (therapeutically or prophylactically), if the extra systoles are the result of an increased sympathetic activity;

– ventricular tachycardia and ventricular fibrillation (prophylactically), especially if the ventricular abnormality is the result of an increased sympathetic activity.

Subject to medical prescription

Pharmaceutical form: 50 mg x 30 film-coated tablets

NHIF code: CF341

ICD: E05.0; E05.1; E05.2; E05.3; E05.4;  I10; I11.9; I12.0; I12.9; I13.1;  I20.0; I20.8; I45.6; I47.1; I48

Description

Nordipin contains amlodipine which belongs to a group of medicines called calcium antagonists. Nordipin works by relaxing blood vessels, improving blood supply to the heart muscle which then receives more oxygen and, as a result, chest pain is prevented.

Indications

Nordipin is indicated for the treatment of:
– hypertension;
– chronic stable angina pectoris;
– vasospastic (Prinzmetal’s) angina.

Subject to medical prescription.

Concentration and pharmaceutical form: 5 mg, 10 mg tablets

Description

Metformin-Tchaikapharma contains metformin, a medicine to treat diabetes. It belongs to a group of medicines called biguanides.

If you have diabetes, your pancreas does not make enough insulin or your body is not able to use properly the insulin it produces. This leads to a high level of glucose in your blood. Metformin-Tchaikapharma helps to lower your blood glucose to as normal a level.

Indications

Metformin-Tchaikapharma is used to treat patients with type 2 diabetes (also called “non-insulin dependent diabetes”) when diet and exercise alone have not been enough to control your blood glucose levels. It is used particularly in overweight patients.

Subject to medical prescription.

Concentration and pharmaceutical form: 850 mg film-coated tablets